| scholarly article | Q13442814 |
| P2093 | author name string | Federica Giannotti | |
| Francesco Buccisano | |||
| Sergio Amadori | |||
| Chiara Sarlo | |||
| Adriano Venditti | |||
| Luca Maurillo | |||
| Maria Ilaria Del Principe | |||
| Massimiliano Postorino | |||
| Daniela Nasso | |||
| Eleonora Ceresoli | |||
| Luigi Di Caprio | |||
| Concetta Ditto | |||
| Marco Refrigeri | |||
| P2860 | cites work | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 |
| The World Health Organization (WHO) classification of the myeloid neoplasms | Q28202501 | ||
| Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B | Q28247684 | ||
| Proposals for the classification of the myelodysplastic syndromes | Q28275931 | ||
| Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients | Q28277777 | ||
| International scoring system for evaluating prognosis in myelodysplastic syndromes | Q28305247 | ||
| Cancer epigenetics comes of age | Q29617275 | ||
| Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress | Q33209607 | ||
| Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. | Q33380148 | ||
| Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry | Q33384383 | ||
| Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes | Q33389465 | ||
| Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy | Q33389755 | ||
| Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study | Q33396282 | ||
| Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia | Q33401766 | ||
| The prognostic significance of auer rods in myelodysplasia | Q72634050 | ||
| Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients | Q73186917 | ||
| Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation | Q73416544 | ||
| Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia | Q74160407 | ||
| Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) | Q79233975 | ||
| MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients | Q80140751 | ||
| Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome | Q80538299 | ||
| Treating the elderly patient with acute myelogenous leukemia | Q83217262 | ||
| Closer to the truth in AML | Q83754455 | ||
| Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program | Q84563146 | ||
| A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial | Q43074202 | ||
| European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy | Q43102335 | ||
| Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study | Q43202683 | ||
| Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial | Q43718516 | ||
| The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial | Q44227814 | ||
| World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. | Q46038765 | ||
| Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia | Q46416418 | ||
| Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system | Q46519220 | ||
| Epigenetic changes in therapy-related MDS/AML. | Q46589950 | ||
| Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial | Q46911781 | ||
| Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. | Q50558385 | ||
| Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients. | Q53511968 | ||
| Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate n | Q53781705 | ||
| Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. | Q54755048 | ||
| Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not oth | Q57740691 | ||
| ??? | Q28202843 | ||
| Chromatin remodeling and leukemia: new therapeutic paradigms. | Q33682713 | ||
| Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome | Q33741025 | ||
| Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine | Q33841988 | ||
| A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome | Q33843955 | ||
| The role of mutations in epigenetic regulators in myeloid malignancies | Q34033164 | ||
| Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 | ||
| Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. | Q34204305 | ||
| Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 | Q34360283 | ||
| Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). | Q34432357 | ||
| Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. | Q34447156 | ||
| Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. | Q34559054 | ||
| Age and acute myeloid leukemia | Q34564663 | ||
| Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial | Q34577028 | ||
| High-dose daunorubicin in older patients with acute myeloid leukemia | Q34612117 | ||
| Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia | Q34615081 | ||
| Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia | Q34615087 | ||
| Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission | Q34621947 | ||
| Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia | Q34659942 | ||
| 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy | Q34770609 | ||
| DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. | Q35032147 | ||
| Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations | Q36220721 | ||
| Acute myeloid leukemia and myelodysplastic syndromes in older patients | Q36815566 | ||
| Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia | Q36862505 | ||
| The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia | Q37195803 | ||
| Interpreting new molecular genetics in myelodysplastic syndromes | Q38066844 | ||
| Discovery of epigenetically silenced genes in acute myeloid leukemias | Q40165138 | ||
| Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study | Q40367786 | ||
| The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes | Q40540562 | ||
| Report of an international working group to standardize response criteria for myelodysplastic syndromes. | Q40737646 | ||
| Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study | Q41123122 | ||
| DNA methylation changes in hematologic malignancies: biologic and clinical implications | Q41455032 | ||
| Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia | Q42720213 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | acute myeloid leukemia | Q264118 |
| P304 | page(s) | e2013032 | |
| P577 | publication date | 2013-06-03 | |
| P1433 | published in | Mediterranean journal of hematology and infectious diseases | Q27723406 |
| P1476 | title | Treatment of acute myeloid leukemia with 20-30% bone marrow blasts | |
| P478 | volume | 5 |
Search more.